Country Progress Report January 2008 - December 2009
Rev Esp Sanid Penit 2012; 14: 11-16 11
Time has seen management for Cystic Fibrosis (CF) advance drastically, most recently in the development of the disease-modifying triple combination therapy ivacaftor/tezacaftor/elexacaftor. There is currently limited evidence regarding both the global epidemiology of CF and access to this transforma...tive therapy - and therefore where needs are not being met. Therefore, this study aims to define gaps in access to CF treatment. The results show that a significant CF patient burden exists in countries where disease-modifying drugs are unavailable, and final figures are likely underestimates. This analysis shows the potential to improve rates of diagnosis and treatment for CF, so a higher percentage of patients receive the most effective triple combination treatment.
more
September 2013
Please download the whole report directly from the website. (Large size 20MB)
PLoS ONE 12(7): e0180996. https://doi.org/10.1371/journal.pone.0180996
International Journal of Infectious Diseases 80 (2019) 10–15
journal homepage: www.elsevier.com/locate/ijid
Infection https://doi.org/10.1007/s15010-024-02408-5
BMC Infectious Diseases 2012, 12:352/1471-2334/12/352
The Lancet Regional Health - Americas 2024;30: 100681
Published Online 3 February 2024 https://doi.org/10.1016/j.lana.2024.100681
School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China
PLOS ONE | www.plosone.org 1, May 2013 | Volume 8 | Issue 5 | e64915